Drug class
Anti-amyloid beta (Aβ) human monoclonal IgG1 antibody; historical Alzheimer disease disease-modifying biologic
Mechanism of action
Binds aggregated soluble and insoluble amyloid beta, including oligomers and fibrils, promoting reduction of amyloid plaque burden. This is the pharmacological rationale; clinical benefit was not established to the level required for continued approval.
General use cases
- Historical US indication: treatment of Alzheimer disease initiated in patients with mild cognitive impairment or mild dementia stage, following confirmation of amyloid pathology. Aduhelm was withdrawn from clinical use and its US approval was withdrawn on 1 November 2024; it is not a current treatment option.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
